Comparing outcomes in viral and bacterial sepsis
Comparative Analysis of Clinical Outcomes and Inflammatory Responses in Viral Versus Bacterial Sepsis: A Retrospective Cohort Study in ICU Patients
Sichuan Provincial People's Hospital · NCT06491966
This study looks at how patients with viral sepsis, especially from COVID-19, compare to those with bacterial sepsis in terms of recovery and inflammation to find better ways to treat them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital (other) |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06491966 on ClinicalTrials.gov |
What this trial studies
This observational cohort study compares clinical outcomes and inflammatory responses between patients with viral sepsis, particularly COVID-19-associated sepsis, and those with bacterial sepsis. Conducted at Sichuan Provincial People's Hospital, it will analyze data from ICU patients admitted between July 2021 and December 2023. The study aims to identify reliable biomarkers and diagnostic methods to enhance patient outcomes through personalized treatment strategies. Key clinical parameters such as mortality rates and inflammatory markers will be evaluated using advanced statistical methods.
Who should consider this trial
Good fit: Ideal candidates include ICU patients aged 18 and older diagnosed with either bacterial or viral sepsis according to Sepsis 3.0 criteria.
Not a fit: Patients with mixed infections or those who do not meet Sepsis 3.0 criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and targeted treatment strategies for sepsis patients.
How similar studies have performed: While studies have explored sepsis outcomes, this specific comparison of viral versus bacterial sepsis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with sepsis according to Sepsis 3.0 criteria. 2. Patients with confirmed bacterial sepsis based on positive bacterial cultures. 3. Patients with confirmed viral sepsis, specifically COVID-19, diagnosed via RT-PCR for SARS-CoV-2 for viral group and negative for bacterial group. 4. Patients aged 18 years and older. 5. Patients admitted to the ICU during the study period. Exclusion Criteria: 1. Patients with mixed bacterial and viral infections. 2. Patients with sepsis not meeting the Sepsis 3.0 criteria. 3. Patients who received immunomodulatory therapies other than standard treatments (e.g., investigational drugs). 4. Pregnant or breastfeeding women.
Where this trial is running
Chengdu, Sichuan
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (RECRUITING)
Study contacts
- Principal investigator: Lin Chen, doctor — Sichuan Provincial People's Hospita
- Study coordinator: Lin Chen, doctor
- Email: chenlinhx@med.uestc.edu.cn
- Phone: 8618111585286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, Sepsis Bacterial, Viral Sepsis, Inflammatory Response, Cytokine Storm, COVID-19, MODS